![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Comparison of the Antivirogram and PhenoSense assays to determine phenotypic susceptibility to rilpivirine in patient samples from the Phase III ECHO and THRIVE trials
|
|
|
Reported by Jules Levin
International Workshop on HIV & Hepatitis Virus
Drug Resistance and Curative Strategies
Sitges, Spain, 5-9 June 2012
Veerle Van Eygen,1 Laurence Rimsky,1 Gaston Picchio,2 Johan Vingerhoets1
1Janssen Infectious Diseases BVBA, Beerse, Belgium; 2Janssen Research & Development LLC, Titusville, NJ, USA
![resistance1.gif](../images/061812/061912-3/resistance1.gif)
![resistance2.gif](../images/061812/061912-3/resistance2.gif)
![resistance3.gif](../images/061812/061912-3/resistance3.gif)
![resistance4.gif](../images/061812/061912-3/resistance4.gif)
![resistance5.gif](../images/061812/061912-3/resistance5.gif)
![resistance6.gif](../images/061812/061912-3/resistance6.gif)
![resistance7.gif](../images/061812/061912-3/resistance7.gif)
![resistance8.gif](../images/061812/061912-3/resistance8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|